Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.psychres.2020.113198 http://scihub22266oqcxt.onion/10.1016/j.psychres.2020.113198 32535509!?!32535509 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32535509&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Psychiatry+Res 2020 ; 291 (?): 113198 Nephropedia Template TP {{tp|p=32535509|t=2020. COVID-19, interferons, and depression: A commentary |pdf=|usr=}}{{32535509}} gab.com Text COVID-19, interferons, and depression: A commentary JO: Psychiatry Res http://www.kidney.de/pget.php?&tw=1&pmid=32535509 #FOAvip An option currently being explored for the treatment of COVID-19 is the use of interferons (INFs), either alone or in combination with other antiviral agents. INFs are known to shift the metabolism of tryptophan (TRP) away from its role as a precursor of serotonin. For some patients, reduction in TRP levels may either expose an underlying vulnerability to depression or trigger a de novo episode of depression. This Commentary discusses the pathway involved and recommends in-hospital augmentation with foods or supplements that increase TRP levels for COVID-19 patients treated with INFs. Selective serotonin reuptake inhibitors may also be tried if the depressive symptomatology is not short-lived. Twit Text FOAVip COVID-19, interferons, and depression: A commentary ????Psychiatry Res http://www.kidney.de/pget.php?&tw=1&pmid=32535509 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32535509 #FOAvip English Wikipedia <ref>{{Cite pmid|32535509}}</ref> COVID-19, interferons, and depression: A commentary #MMPMID32535509 Shader RI Psychiatry Res 2020[Sep]; 291 (?): 113198 PMID32535509show ga An option currently being explored for the treatment of COVID-19 is the use of interferons (INFs), either alone or in combination with other antiviral agents. INFs are known to shift the metabolism of tryptophan (TRP) away from its role as a precursor of serotonin. For some patients, reduction in TRP levels may either expose an underlying vulnerability to depression or trigger a de novo episode of depression. This Commentary discusses the pathway involved and recommends in-hospital augmentation with foods or supplements that increase TRP levels for COVID-19 patients treated with INFs. Selective serotonin reuptake inhibitors may also be tried if the depressive symptomatology is not short-lived. |*Betacoronavirus[MESH] |COVID-19[MESH] |Coronavirus Infections/*metabolism/*psychology[MESH] |Depression/*metabolism/psychology[MESH] |Humans[MESH] |Interferons/*metabolism[MESH] |Pandemics[MESH] |Pneumonia, Viral/*metabolism/*psychology[MESH] |SARS-CoV-2[MESH] |Serotonin/metabolism[MESH]COVID-19, interferons, and depression: A commentary (epmc).pdf DeepDyve Pubget Overpricing